ReviewCancer2025
Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023-2024.
Review in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Short-course immunotherapy in surgically resectable, high risk cutaneous squamous cell carcinoma.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Conversion-intent PD-1-based chemoimmunotherapy restores surgical feasibility in borderline resectable or unresectable non-head-and-neck cutaneous squamous cell carcinoma.The oncologist · 2026Article
- Management of Advanced Cutaneous Squamous Cell Carcinoma over the Last Decade: A Single-Centre Retrospective Study.Current oncology (Toronto, Ont.) · 2026Article
- Potential Efficacy of Luteolin in Cutaneous Squamous Cell Carcinoma: A Combined In Vitro and In Vivo Study.Biomolecules · 2026Article
- Review
- Review
- Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023-2024.Cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibodies against PD-1 (PD1i), such as cemiplimab and pembrolizumab, have demonstrated significant efficacy in advanced, unresectable cutaneous squamous cell carcinoma (cSCC). These agents elicit durable responses in approximately 45% of patients, contributing to improved aesthetic, functional, and survival outcomes in a subset of individuals with advanced cSCC. This review highlights recent and ongoing research investigating the safety and efficacy of immune checkpoint inhibitors for cSCC in the curative intent perioperative settings, advanced/metastatic setting, and within the immunocompromised patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.